Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DP303c
- Development stage
- Phase 3
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DP303c is a site-specific anti-HER2 antibody-drug conjugate (ADC) developed for the treatment of HER2-positive advanced solid tumors, especially breast cancer. It consists of a monoclonal antibody that selectively binds to the human epidermal growth factor receptor 2 (HER2), conjugated via a cleavable linker to the cytotoxic payload monomethyl auristatin E (MMAE). The average drug-to-antibody ratio (DAR) is approximately 2.0. Preclinical and clinical studies have demonstrated that DP303c exhibits promising anti-tumor activity with an acceptable safety profile in patients with pre-treated advanced HER2-positive solid tumors. The recommended phase 2 dose is 3.0 mg/kg administered intravenously every three weeks[2][6][8].
- Other names
- ADC DP303cantibody-drug conjugate DP303c
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on DP303c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DP303c.